About Owen Gallagher
Owen Gallagher is a clinical research professional turned medical writer who spent years inside the machinery of obesity clinical trials before picking up a pen to explain them to the rest of us. He earned his Master of Science in Clinical Research from Duke University School of Medicine, where he trained in biostatistics, regulatory science, and clinical trial methodology — the nuts-and-bolts disciplines that determine whether a weight loss drug actually works or just looks good in a press release. His graduate work focused on endpoint selection and outcome measurement in obesity pharmacotherapy trials, giving him an unusually detailed understanding of how trial design choices shape the headlines patients eventually read.
After Duke, Owen worked as a clinical research coordinator at an academic medical center, where he helped run Phase III and Phase IV obesity and metabolic disease trials. He recruited and screened participants, managed adverse event reporting, coordinated data collection across multi-site protocols, and watched firsthand as drugs like semaglutide and tirzepatide moved through the clinical pipeline. He has hands-on familiarity with the STEP and SURMOUNT trial frameworks — not from reading the publications, but from working within the operational structures those trials required. That experience gave him something rare in health writing: the ability to look at a clinical trial result and immediately identify what the data actually shows versus what the marketing department wants you to think it shows.
Owen now channels that expertise into medical writing for Losing Weight RX, where he covers GLP-1 receptor agonists, metabolic biomarkers, and the evolving evidence base for pharmacological weight loss interventions. His articles are built for readers who want more than surface-level summaries — he breaks down study designs, explains what "statistically significant" really means in context, unpacks secondary endpoints that the headlines skip, and flags the limitations that even good studies carry. He writes with the precision of someone who has filled out case report forms and the clarity of someone who remembers what it was like to explain a trial protocol to a nervous participant for the first time.
Articles by Owen Gallagher
Boehringer Details Survodutide Phase 3 SYNCHRONIZE Data
June 7, 2026
Lilly Details Phase 3 Retatrutide TRIUMPH-1 Results
June 6, 2026
Lilly Details Retatrutide TRANSCEND-T2D-1 Results
June 5, 2026
ASCO 2026: GLP-1 Receptor Agonists Associated with 30% Lower Breast Cancer Risk
June 4, 2026
ACHIEVE-4 Trial: Oral Orforglipron Shows Cardiac Safety
June 3, 2026
AstraZeneca to Push Oral GLP-1 Elecoglipron into Phase 3
June 2, 2026
ASCO 2026: GLP-1 Drugs Cut Endometrial Cancer Mortality by 55%
June 1, 2026
FDA Advisory Panel to Review BPC-157, TB-500 and 5 Other Peptides in July
May 30, 2026